What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Sell
14
JDHIF Quote, Financials, Valuation and Earnings
Last price:
$7.07
Seasonality move
:
-6.49%
Day range:
$7.07 - $7.07
52-week range:
$3.13 - $8.75
Dividend yield:
0%
P/E ratio:
34.37x
P/S ratio:
2.49x
P/B ratio:
2.95x
Volume:
--
Avg. volume:
344
1-year change:
126.24%
Market cap:
$22.6B
Revenue:
$8.1B
EPS (TTM):
$0.21
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JDHIF
JD Health International, Inc.
|
-- | -- | -- | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -$0.34 | -- | -- | $9.22 |
|
CASI
CASI Pharmaceuticals, Inc.
|
-- | -- | -100% | -- | $4.00 |
|
CPHI
China Pharma Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$138M | -$0.28 | 16.92% | -46.43% | $49.49 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JDHIF
JD Health International, Inc.
|
$7.07 | -- | $22.6B | 34.37x | $0.00 | 0% | 2.49x |
|
ADAG
Adagene, Inc.
|
$1.75 | $9.22 | $82.4M | -- | $0.00 | 0% | 787.59x |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.86 | $4.00 | $17.7M | -- | $0.00 | 0% | 0.50x |
|
CPHI
China Pharma Holdings, Inc.
|
$1.55 | -- | $5.1M | -- | $0.00 | 0% | 1.25x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
ZLAB
Zai Lab Ltd.
|
$17.77 | $49.49 | $2B | -- | $0.00 | 0% | 4.32x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JDHIF
JD Health International, Inc.
|
-- | 0.951 | -- | 3.39x |
|
ADAG
Adagene, Inc.
|
26.49% | 2.508 | -- | 2.23x |
|
CASI
CASI Pharmaceuticals, Inc.
|
-274.41% | 0.019 | 55.28% | 0.19x |
|
CPHI
China Pharma Holdings, Inc.
|
29.58% | -1.772 | 56.09% | 0.09x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.067 | 12.91% | 11.22x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | 0.005 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JDHIF
JD Health International, Inc.
|
-- | -- | 8% | 8% | -- | -- |
|
ADAG
Adagene, Inc.
|
-- | -- | -42.07% | -56.44% | -- | -- |
|
CASI
CASI Pharmaceuticals, Inc.
|
$706K | -$10.2M | -405.32% | -70405.41% | -333.14% | -- |
|
CPHI
China Pharma Holdings, Inc.
|
-$257.6K | -$628.1K | -29.08% | -43.41% | -83.07% | -$277.6K |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
JD Health International, Inc. vs. Competitors
-
Which has Higher Returns JDHIF or ADAG?
Adagene, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of --. JD Health International, Inc.'s return on equity of 8% beat Adagene, Inc.'s return on equity of -56.44%.
Company Gross Margin Earnings Per Share Invested Capital JDHIFJD Health International, Inc.-- -- $7.6B ADAGAdagene, Inc.-- -- $68.7M -
What do Analysts Say About JDHIF or ADAG?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Adagene, Inc. has an analysts' consensus of $9.22 which suggests that it could grow by 427.1%. Given that Adagene, Inc. has higher upside potential than JD Health International, Inc., analysts believe Adagene, Inc. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIFJD Health International, Inc.0 0 0 ADAGAdagene, Inc.6 2 0 -
Is JDHIF or ADAG More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Adagene, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock JDHIF or ADAG?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagene, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Adagene, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIF or ADAG?
JD Health International, Inc. quarterly revenues are --, which are smaller than Adagene, Inc. quarterly revenues of --. JD Health International, Inc.'s net income of -- is lower than Adagene, Inc.'s net income of --. Notably, JD Health International, Inc.'s price-to-earnings ratio is 34.37x while Adagene, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.49x versus 787.59x for Adagene, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIFJD Health International, Inc.2.49x 34.37x -- -- ADAGAdagene, Inc.787.59x -- -- --
-
Which has Higher Returns JDHIF or CASI?
CASI Pharmaceuticals, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of -353.92%. JD Health International, Inc.'s return on equity of 8% beat CASI Pharmaceuticals, Inc.'s return on equity of -70405.41%.
Company Gross Margin Earnings Per Share Invested Capital JDHIFJD Health International, Inc.-- -- $7.6B CASICASI Pharmaceuticals, Inc.22.96% -$0.68 -$6.9M -
What do Analysts Say About JDHIF or CASI?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand CASI Pharmaceuticals, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 363.5%. Given that CASI Pharmaceuticals, Inc. has higher upside potential than JD Health International, Inc., analysts believe CASI Pharmaceuticals, Inc. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIFJD Health International, Inc.0 0 0 CASICASI Pharmaceuticals, Inc.1 0 0 -
Is JDHIF or CASI More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CASI Pharmaceuticals, Inc. has a beta of 0.853, suggesting its less volatile than the S&P 500 by 14.657%.
-
Which is a Better Dividend Stock JDHIF or CASI?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CASI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. CASI Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIF or CASI?
JD Health International, Inc. quarterly revenues are --, which are smaller than CASI Pharmaceuticals, Inc. quarterly revenues of $3.1M. JD Health International, Inc.'s net income of -- is lower than CASI Pharmaceuticals, Inc.'s net income of -$10.9M. Notably, JD Health International, Inc.'s price-to-earnings ratio is 34.37x while CASI Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.49x versus 0.50x for CASI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIFJD Health International, Inc.2.49x 34.37x -- -- CASICASI Pharmaceuticals, Inc.0.50x -- $3.1M -$10.9M
-
Which has Higher Returns JDHIF or CPHI?
China Pharma Holdings, Inc. has a net margin of -- compared to JD Health International, Inc.'s net margin of -86.16%. JD Health International, Inc.'s return on equity of 8% beat China Pharma Holdings, Inc.'s return on equity of -43.41%.
Company Gross Margin Earnings Per Share Invested Capital JDHIFJD Health International, Inc.-- -- $7.6B CPHIChina Pharma Holdings, Inc.-34.07% -$0.17 $12.1M -
What do Analysts Say About JDHIF or CPHI?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand China Pharma Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that JD Health International, Inc. has higher upside potential than China Pharma Holdings, Inc., analysts believe JD Health International, Inc. is more attractive than China Pharma Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIFJD Health International, Inc.0 0 0 CPHIChina Pharma Holdings, Inc.0 0 0 -
Is JDHIF or CPHI More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison China Pharma Holdings, Inc. has a beta of 1.028, suggesting its more volatile than the S&P 500 by 2.826%.
-
Which is a Better Dividend Stock JDHIF or CPHI?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. China Pharma Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. China Pharma Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIF or CPHI?
JD Health International, Inc. quarterly revenues are --, which are smaller than China Pharma Holdings, Inc. quarterly revenues of $756.2K. JD Health International, Inc.'s net income of -- is lower than China Pharma Holdings, Inc.'s net income of -$651.5K. Notably, JD Health International, Inc.'s price-to-earnings ratio is 34.37x while China Pharma Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.49x versus 1.25x for China Pharma Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIFJD Health International, Inc.2.49x 34.37x -- -- CPHIChina Pharma Holdings, Inc.1.25x -- $756.2K -$651.5K
-
Which has Higher Returns JDHIF or SVA?
Sinovac Biotech Ltd. has a net margin of -- compared to JD Health International, Inc.'s net margin of --. JD Health International, Inc.'s return on equity of 8% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital JDHIFJD Health International, Inc.-- -- $7.6B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About JDHIF or SVA?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that JD Health International, Inc. has higher upside potential than Sinovac Biotech Ltd., analysts believe JD Health International, Inc. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings JDHIFJD Health International, Inc.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is JDHIF or SVA More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.723, suggesting its less volatile than the S&P 500 by 27.741%.
-
Which is a Better Dividend Stock JDHIF or SVA?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIF or SVA?
JD Health International, Inc. quarterly revenues are --, which are smaller than Sinovac Biotech Ltd. quarterly revenues of --. JD Health International, Inc.'s net income of -- is lower than Sinovac Biotech Ltd.'s net income of --. Notably, JD Health International, Inc.'s price-to-earnings ratio is 34.37x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.49x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIFJD Health International, Inc.2.49x 34.37x -- -- SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns JDHIF or ZLAB?
Zai Lab Ltd. has a net margin of -- compared to JD Health International, Inc.'s net margin of -30.98%. JD Health International, Inc.'s return on equity of 8% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital JDHIFJD Health International, Inc.-- -- $7.6B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About JDHIF or ZLAB?
JD Health International, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $49.49 which suggests that it could grow by 178.49%. Given that Zai Lab Ltd. has higher upside potential than JD Health International, Inc., analysts believe Zai Lab Ltd. is more attractive than JD Health International, Inc..
Company Buy Ratings Hold Ratings Sell Ratings JDHIFJD Health International, Inc.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is JDHIF or ZLAB More Risky?
JD Health International, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.872, suggesting its less volatile than the S&P 500 by 12.778%.
-
Which is a Better Dividend Stock JDHIF or ZLAB?
JD Health International, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. JD Health International, Inc. pays -- of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JDHIF or ZLAB?
JD Health International, Inc. quarterly revenues are --, which are smaller than Zai Lab Ltd. quarterly revenues of $116.2M. JD Health International, Inc.'s net income of -- is lower than Zai Lab Ltd.'s net income of -$36M. Notably, JD Health International, Inc.'s price-to-earnings ratio is 34.37x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for JD Health International, Inc. is 2.49x versus 4.32x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JDHIFJD Health International, Inc.2.49x 34.37x -- -- ZLABZai Lab Ltd.4.32x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Is JetBlue The Best Airline Stock?
Following a general trend of improvement among airline stocks, shares…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 5.6% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 3.65% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 3.6% over the past day.
